CRISPR/$CRSP

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About CRISPR

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Ticker

$CRSP
Primary listing

Industry

Biotechnology

Headquarters

Zug, Switzerland

Employees

393

ISIN

CH0334081137

CRISPR Metrics

BasicAdvanced
$4.1B
-
-$4.52
1.87
-

What the Analysts think about CRISPR

Analyst ratings (Buy, Hold, Sell) for CRISPR stock.

Bulls say / Bears say

CRISPR Therapeutics' gene therapy, Casgevy, received FDA approval for treating sickle cell disease and transfusion-dependent beta thalassemia, marking a significant milestone in gene-editing treatments. (Wikipedia)
The company maintains a robust cash position of approximately $1.9 billion, providing a substantial runway for ongoing research and development initiatives. (SECsense)
CRISPR Therapeutics is expanding its pipeline into autoimmune diseases, diversifying its portfolio and potentially opening new revenue streams. (Simply Wall St)
Despite the approval of Casgevy, CRISPR Therapeutics reported a widened net loss of $366 million in 2024, raising concerns about its path to profitability. (Panabee)
The company's accumulated deficit has grown to $1.366 billion, indicating ongoing financial challenges and potential future funding difficulties. (SECsense)
Vertex Pharmaceuticals holds significant control over the Casgevy program, which may limit CRISPR Therapeutics' decision-making and impact its commercial success. (Panabee)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

CRISPR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CRISPR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CRSP

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs